Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

NeoDynamics

NeoDynamics Sweden

12.11.2020 - 09:20:06

NeoDynamics enters a scientific partnership to evaluate its technology platform in osteoarthritis

STOCKHOLM, Nov. 12, 2020 /PRNewswire/ -- NeoDynamics AB (publ), (Spotlight Stockholm: NEOD), today announced that the Company joins in a research collaboration with the William Hunter Revisited research consortium to evaluate NeoNavia pulse biopsy system for joint tissue sampling in a new potential indication, osteoarthritis.

The William Hunter Revisited research consortium consists of six universities and academic hospitals and is collaborating with industry to identify biomarkers and test new diagnostic devices for monitoring disease progression and repair as well as developing regenerative therapies for osteoarthritis.

"We look forward to collaborating with NeoDynamics and leveraging their expertise and technology to improve biopsy technique and tissue sampling in patients with osteoarthritis", says Dr. Pieter Emans, Orthopedic Surgeon at Maastricht UMC.

"The collaboration with the consortium is a great opportunity for NeoDynamics, it gives us access to a network of leading clinicians and researchers in the field of osteoarthritis. Naturally we are interested to evaluate our technology platform beyond the breast cancer area", says Kai-Uwe Schässburger, Ph.D. Director Clinical Development & Medical Affairs of NeoDynamics. "This will further validate our pulse biopsy system NeoNavia and explore the potential use in Osteoarthritis".

Osteoarthritis is the most common form of arthritis, affecting more than 100 million patients around the world. It occurs when the protective cartilage that cushions the end of the bones gradually deteriorates and is the 4th leading cause of mobility-associated disability. Osteoarthritis is a degenerative disease that worsens over time often resulting in chronic pain. Societal costs are immense and reaching 15 Billion per year in the Netherlands alone. There is a significant need to developing innovative tools for tissue sampling, and analysis of disease progression to optimize individual treatment options.

The information was submitted for publication through the agency of the contact person set out below, at 08:55 CET on November 12, 2020

For additional information please contact: 

Anna Eriksrud, CEO NeoDynamics AB (publ). Phone +46 708 444 966 e-mail: anna.eriksrud@neodynamics.com

Jörgen Vrenning, CFO/IR NeoDynamics AB (publ). Phone +46 708 519 648 e-mail: jorgen.vrenning@neodynamics.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/neodynamics/r/neodynamics-enters-a-scientific-partnership-to-evaluate-its-technology-platform-in-osteoarthritis,c3235576

 

@ prnewswire.co.uk